In the REDHART trial, 60 patients with LVEF <50%, recent hospitalization for decompensated HF and elevated CRP levels (>2 mg/L), within 14 days of hospital discharge, were randomized 1:1:1 to daily subcutaneous injections with anakinra 100 mg for 2 weeks, 12 weeks, or placebo. The gene discussed is CRP; the disease is hydrops fetalis.